重组人内皮单核细胞激活多肽II蛋白 rHuEMAP-II 上海康朗生物科技有限公司

如果您对该产品感兴趣的话，可以
产品名称：重组人内皮单核细胞激活多肽II蛋白
产品型号：rHuEMAP-II
产品展商：KALANG
产品文档：无相关文档
发布时间：2018-07-16
在线询价

简单介绍

重组人内皮单核细胞激活多肽II蛋白与其它公司提供的重组蛋白不同，rHuEMAP-II蛋白产品为采用CFS的无细胞麦胚蛋白合成系统表达出来的重组蛋白，可表达出对细胞有毒性、易被蛋白酶降解的蛋白；并获得具有良好的可溶性，并有翻译后修饰、从而部分具有功能的蛋白.同时独有的全自动蛋白纯化技术则简便高效，将蛋白纯化过程中对蛋白的损伤降低到*小程度.重组人内皮单核细胞激活多肽II蛋白（全长序列）产品可用于Western Blot验证、抗体制备、蛋白检测、ELISA等试验中.

产品描述

重组人内皮单核细胞激活多肽II蛋白

Synonyms	SCYE1, EMAP-2, Small Inducible Cytokine Subfamily E Member 1
Species	Human
Accession	Q12904
GeneID	9255
Source	Escherichia coli.
Molecular Weight	重组人内皮单核细胞激活多肽II蛋白Approximately 18.2 kDa, a single non-glycosylated polypeptide chain containing 166 amino acids.
Quantity	5µg/20µg/1000µg
AA Sequence	SKPIDVSRLD LRIGCIITAR KHPDADSLYV EEVDVGEIAP RTVVSGLVNH VPLEQMQNRM VILLCNLKPA KMRGVLSQAM VMCASSPEKI EILAPPNGSV PGDRITFDAF PGEPDKELNP KKKIWEQIQP DLHTNDECVA TYKGVPFEVK GKGVCRAQTM SNSGIK
Purity	> 98 % by SDS-PAGE and HPLC analyses.
Biological Activity	重组人内皮单核细胞激活多肽II蛋白Fully biologically active when compared to standard. The ED₅₀ as determined by the apoptotic effect using serum free human MCF-7 cells is less than 40 ng/ml, corresponding to a specific activity of > 2.5 × 10⁴ IU/mg.
Physical Appearance	Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation	Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
Endotoxin	Less than 1 EU/μg of rHuEMAP-II as determined by LAL method.
Reconstitution	重组人内皮单核细胞激活多肽II蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Storage	This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.
重组人内皮单核细胞激活多肽II蛋白
SDS-PAGE
Reference	1. Awasthi N, Schwarz MA, Schwarz RE. 2010. Cancer Biol Ther, 10: 99-107. 2. Journeay SandSingh B. 2007. Acta Neuropathol, 114: 435; author reply 7-8. 3. Clarijs R, Schalkwijk L, Ruiter DJ, et al. 2003. Invest Ophthalmol Vis Sci, 44: 1801-6. 4. Kayton MLandLibutti SK. 2001. Curr Opin Investig Drugs, 2: 136-8.
Background	Endothelial-Monocyte Activating Polypeptide II (EMAP-II) is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues.